Are Incentives Out Of Balance With Patient Need?
Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.
You may also be interested in...
Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.
Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.
The Innovative Medicines Fund, due for launch in England later this year, may provide industry with an opportunity to hold key public bodies to account.